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Many mammalian receptor domains, among them a large
number of potential therapeutic target proteins, are highly
aggregation-prone upon heterologous expression in bac-
teria. This severely limits functional studies of such receptor
domains and also their engineering towards improved prop-
erties. One of these proteins is the Nogoreceptor, which plays
a central role in mediating the inhibition of axon growth and
functional recovery after injury of the adult mammalian
central nervous system. We show here that the ligand bind-
ing domain of the Nogoreceptor folds to an active conforma-
tion in ternary ribosomal complexes, as formed in ribosome
display. In these complexes the receptor is still connected, via
a C-terminal tether, to the peptidyl tRNA in the ribosome
and the mRNA also stays connected. The ribosome prevents
aggregation of the protein, which aggregates as soon as the
release from the ribosome is triggered. In contrast, no active
receptor was observed in phage display, where aggregation
appears to prevent incorporation of the protein into the
phage coat. This strategy sets the stage for rapidly studying
defined mutations of such aggregation-prone receptors
in vitro and to improve their properties by in vitro evolution
using the ribosome display technology.
Keywords: in vitro evolution/nogo receptor/protein
aggregation/protein folding/ribosome display
Introduction
Many proteins of mammalian origin are highly aggregation-
prone upon heterologous expression, including a large number
of potential therapeutic target proteins. These include in par-
ticular mammalian receptor domains, which can rely on the
complex folding machinery of the eukaryotic cell for secreted
proteins (Ellgaard et al., 1999) and on glycosylation to improve
their solubility (Wyss et al., 1995) and stability (Wormald and
Dwek, 1999). In contrast, combinatorial selection technologies
such as phage display and ribosome display do not provide this
environment, as phage display exploits the pathway of bacterial
secretion, whereas ribosome display occurs in an in vitro trans-
lation extract. Both methods are powerful tools for the iden-
tification of proteins that bind to a given target molecule and
also for the directed evolution of proteins towards improved
properties such as binding affinity and stability. Even though
these technologies are well established for peptides, antibody
fragments and other classes of proteins that are expressed
at least to some level in soluble and functional form in
prokaryotic expression systems (Dunn, 1996; Hanes and
Plu¨ckthun, 1997; Binz et al., 2004), other mammalian proteins
may not be amenable to these display technologies. Even the
investigation of point mutants of such receptors is laborious, as
they have to be expressed and tested in eukaryotic systems.
An important class of mammalian receptor domains being
involved in a large variety of different interactions is the family
of extracellular leucine-rich repeat (LRR) domains (Kobe and
Kajava, 2001). Despite their important role and crucial parti-
cipation in a number of diseases, structural und functional
investigations of these domains have proven very difficult,
as their heterologous expression in Escherichia coli has
often only yielded aggregated protein and refolding attempts
for members of this class have achieved only very limited
success (Hering et al., 1996; Lobel et al., 2002).
One member of particular interest in this class of proteins is
the Nogoreceptor, which interacts with several myelin-
associated proteins responsible for inhibiting axonal regenera-
tion after injury in the adult mammalian central nervous system
(CNS). Initially, it had been identified as a binding site for the
short 66-amino acid extracellular domain of Nogo, termed
Nogo-66 (Fournier et al., 2001). Nogo is a potent inhibitor
of axonal sprouting and functional recovery after spinal
chord injury (Chen et al., 2000; GrandPre et al., 2000). Recent
findings suggest the Nogoreceptor to be a point of convergence
in signal transduction for several of these inhibitors, indicating
that this receptor is indeed a key player in regulating axonal
regeneration and plasticity in the adult CNS (McGee and
Strittmatter, 2003). The Nogoreceptor is a glycosylphos-
phatidylinositol (GPI)-anchored receptor and represents a
typical member of the class of extracellular LRR domains.
The LRR core region is represented by 8.5 LRR modules,
flanked by cysteine-rich N-terminal and C-terminal ‘capping’
modules, which both contain two disulfide bridges (He et al.,
2003). The core region is glycosylated with sugar moieties
modifying Asn82 and Asn179. A unique C-terminal region
of 100 amino acids follows the LRR domain, which is not
required for Nogo-66 binding, but plays a role in the interaction
with the coreceptor p75 (Wang et al., 2002). The LRR domain
of the Nogoreceptor has been found to be necessary and suf-
ficient for binding to Nogo-66 (Fournier et al., 2002). Import-
antly, soluble Nogoreceptor–Fc fusion protein has been found
to antagonize the growth-inhibiting effects of Nogo in in vitro
neurite outgrowth assays. Because of the great interest in
attempting to stimulate axonal regrowth after spinal chord
injuries or stroke, the Nogoreceptor and its ligands represent
important drug targets for modulating axonal regeneration. The
Nogoreceptor is therefore an especially interesting target for
protein engineering and directed protein evolution with the
potential of creating variants of higher affinity or stability.
We examined whether ribosome display technology can be
applied to such mammalian receptors, even though their het-
erologous expression in bacteria does not yield natively folded
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protein. We were not only able to obtain soluble ternary com-
plexes of RNA, ribosome and receptor domains, but also to
reconstitute the interaction between Nogoreceptor and Nogo-
66 in vitro. In contrast, we did not observe functionally
displayed Nogoreceptor protein in a standard phage display
system. This finding paves the way for evolving receptor
domains with improved properties for developing them into
drugs. Moreover, we show that the established assay can be
used as a versatile screening tool for studying structure–
function relationships in vitro on a very rapid time-scale.
Materials and methods
Preparation of plasmids and mRNA
Nogo-66 fusion constructs. A full-length clone of Nogo-A
(HUGE database: KIAA0886; GenBank accession No.
AB020693) was generously provided by the Kazusa DNA
Research Institute. Plasmid pBMS053 encoding a C-terminal
fusion of the extracellular domain of Nogo-A (Nogo-66, resi-
dues 1055–1120) (GrandPre et al., 2000) to protein D (residues
T20–V109 of bacteriophage l gpD) (Yang et al., 2000) with
an N-terminal Avi-tag and a C-terminal His-tag is a derivative
of pAT221, a version of pAT222 (GenBank accession
No. AY327137) with a different reading frame. The Nogo-
66 gene fragment was polymerase chain reaction (PCR) amp-
lified and ligated into the BamHI/HindIII sites of pAT221.
Plasmid pBMS043 encoding a C-terminal fusion of Nogo-66
to E.coli thioredoxin (GeneBank accession No. M26133) with
an N-terminal His-tag is a derivative of pAT194 (P.Forrer,
unpublished work), which is derived from pQE30, but contains
a gene fragment coding for protein D after the His-tag
followed by unique restriction sites. The thioredoxin gene frag-
ment was amplified and ligated into the NcoI/BamHI sites of
pAT194 replacing the protein D gene fragment. The PCR-
amplified fragment coding for Nogo-66 was inserted between
the BamHI/HindIII sites at the 30-end of the thioredoxin gene.
Nogoreceptor variants. Macaca fascicularis Nogoreceptor
cDNA (GenBank accession No. AB045987) was a kind gift
from the National Institute of Infectious Diseases, Japan. For
ribosome display, Nogoreceptor variants were cloned into plas-
mid pRDV2, a derivative of pRD-n1n2_2 (Matsuura and
Plu¨ckthun, 2003) with a T7 promoter introduced. A gene frag-
ment encoding the ligand binding domain of the macaque
Nogoreceptor (residues 24–331) comprising the N-terminal
flanking region (LRR-NT), the LRR core region, the C-
terminal LRR flanking region (LRR-CT) and an additional
short overhang, was inserted in front of the protein D (pD)-
linker via NcoI and BamHI after PCR amplification. We
had previously substituted residues C316 and L329 in the over-
hang by the respective residues of the human Nogoreceptor.
The final PCR amplification resulted in construct NR
(Figure 2).
To generate a variant in which the two free cysteines at
positions 80 and 140 in the LRR core region are replaced
by the respective consensus residues at each position (C80L
and C140N), PCR-directed mutagenesis was performed result-
ing in construct NRC. Deletion mutant NRCDLRR-CT lack-
ing the C-terminal LRR-flanking region comprises residues
24–260 and both consensus mutations. Deletion mutant
LRR-CT comprises only the C-terminal LRR flanking region
(residues 261–314). mRNA of all variants was produced by
in vitro transcription and purified as described previously
(Schaffitzel et al., 2001).
For phage display, gene fragments NR and NRC were
PCR amplified with oligonucleotides GGAAAAAGCTCTT-
CACCCCTGTTACCAAAGCCGACTACAAAGATGCAGC-
CCCGTGCCCAGGCG and GGAAAAGAATTCCCCCAGC-
GGCTCCTCGTCGG introducing the restriction sites EcoRI at
the 30-end and SapI at the 50-end, which is located within the
phoA signal sequence, the remaining portion of the phoA signal
sequence and the N-terminal FLAG-tag. The fragments
were then cloned into the phagemid vector pMorph7
(Morphosys AG), where the construct is placed between a
phoA signal sequence and the C-terminal domain of the
gene 3 protein (g3p). As a control for the binding competency
of the NR and NRC displaying phage, we also prepared
phages displaying the single-chain Fv antibody alFv1, which
binds specifically to Nogo-66 and which had previously been
obtained by phage panning of the HuCAL library (Morphosys)
(Knappik et al., 2000) against different Nogo-66 fusion
proteins (B.Schimmele, unpublished results).
Human biglycan cDNA was kindly provided by the Mam-
malian Gene Collection (clone MGC_19). The gene fragment
encoding the core protein (residues 60–368) was PCR ampli-
fied as two overlapping fragments, because the gene contains
an internal NcoI site and the two gene fragments were
simultaneously ligated into pRDV2 after restriction with
NcoI/HincII and HincII/BamHI.
Preparation of Nogo-66 fusion proteins
Nogo-66 fusion proteins were expressed as inclusion bodies in
E.coli C41 (pREP4) (Miroux and Walker, 1996). Expression
was continued for 4 h after induction with 1 mM IPTG at 37C.
Cells were collected by centrifugation, resuspended in 50 mM
Tris–HCl (pH 8.0), 150 mM NaCl, 4 mM MgCl2, 20 mg/ml
DNase I and lysed with an Emulsiflex-C5 (Avestin). Inclusion
bodies were collected by centrifugation and washed three times
with 50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1% Triton.
Inclusion bodies were then solubilized with 6 M GdnHCl,
50 mM Tris–HCl, 150 mM NaCl (pH 8.0) and, after centrifu-
gation, proteins were purified on a Ni-NTA column under
denaturing conditions according to the manufacturer’s instruc-
tions (Qiagen, Germany). After purification, DTT was added to
a final concentration of 50 mM. Refolding was performed by
fast dilution from a 650 mM protein stock solution into 50 mM
Tris–HCl, 150 mM NaCl, pH 8.5.
For coating of paramagnetic polystyrene beads (M-270-
Epoxy, Dynal Biotech), fusion proteins were extensively dia-
lysed against PBS (pH 8.0). Soluble refolded fusion protein at a
final concentration of 14 mM in PBS in 1 M ammonium sulfate
was rotated for 60 h at 4C with 2 · 108 beads/ml. Beads were
prepared and blocked according to the manufacturer’s instruc-
tions. Coated beads were stored at 4C in PBS (pH 8.0),
0.002% Tween-20 for no longer than 1 week. For inhibition
studies protein was rebuffered into WBKT buffer (see below)
on a NAP-5 column (Amersham Biosciences) after refolding
by fast dilution.
Size-exclusion chromatography
Refolded protein samples at a concentration of 20 mM in 50 mM
Tris, 150 mM NaCl, pH 8.5 were applied to a Superdex 200
column (Amersham Biosciences) and the elution profiles were
monitored by measuring the absorbance at 280 and 230 nm.
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Static light scattering and refractive index detection were per-
formed in-line by a coupled miniDawn tri-angle light-
scattering and an Optilab refractive index detector (Wyatt
Technology). Molecular mass was calculated with a dn/dc
value of 0.185.
Circular dichroism (CD) spectra
Experiments were performed on a J-715 spectropolarimeter
(Jasco) at 4C with 20 mM protein in 50 mM borate,
150 mM NaCl, pH 8.5 or the respective Tris-based buffer
system using cuvettes with 1 mm pathlength. Data from
four independent scans were averaged.
Binding studies
In vitro translations were carried out as described previously
(Schaffitzel et al., 2001) with addition of [35S]methionine.
After 10 min at 37C, the translation reaction was stopped
by 5-fold dilution with ice-cold WBK500T buffer (50 mM
Tris–acetate, pH 7.5, 150 mM NaCl, 50 mM magnesium
acetate, 0.5 M KCl, 0.1% Tween-20) containing 2.5 mg/ml
heparin. After centrifugation at 11 000 g for 5 min, the ternary
complexes of RNA, ribosomes and protein were further puri-
fied by ultracentrifugation through a sucrose cushion. For this
purpose, 500 ml of supernatant were applied to 2.5 ml of 35%
sucrose in WBKT (50 mM Tris–acetate, pH 7.5, 150 mM NaCl,
50 mM magnesium acetate, 250 mM KCl, 0.1% Tween-20) and
ultracentrifugation was carried out at 100 000 g for 20 min. The
pellet was resuspended in WBKT and binding experiments
were carried out in the presence of bovine serum albumin
(BSA) (final concentration of 5 mg/ml) and Saccharomyces
cerevisiae RNA (final concentration of 250 mg/ml). Equal
amounts of ternary complexes were mixed with either
WBKT or defined concentrations of Nogo-66 fusion protein
in WBKT for competition. After shaking the mixture for 30 min
at 4C, 107 paramagnetic beads, coated with fusion proteins
and equilibrated with WBKT, were added and the solution was
shaken for 1 h at 4C. For capturing ternary complexes via the
N-terminal His-tag, mixtures were preincubated with 0.1 mg of
Fig. 1. Analysis of recombinant Nogo-66. (A and B) Nogo-66 with Avi- and His-tag, (C and D) pD–Nogo-66 fusion protein with Avi- and His-tag. The recombinant
Nogo-66 fusion proteins are depicted schematically on top of the panels. (A and C) Size-exclusion chromatography of Nogo-66 constructs. Purified proteins were
analysed by SDS–PAGE (15%) (inset), refolded by fast dilution into 50 mM Tris, 150 mM NaCl (pH 8.5), loaded on a Superdex 200 column and eluted with the same
buffer. TheA280 traces (left-hand axis) are shown. Gel filtration was followed by in-line multi-angle light scattering. Light scattering data converted to molecular mass
are represented as clustered points for the pD–Nogo-66 fusion protein (right-hand axis). The average molecular mass of eluted pD–Nogo-66 is23 kDa, corresponding
to the mass of monomeric protein. (B and D) CD spectra for both proteins. Spectra were recorded at 4C in borate buffer (pH 8.5).
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anti-RGS-His-tag antibody (Qiagen) and subsequently immob-
ilized on Dynabeads containing immobilized protein G (Dynal
Biotech). After incubation, the beads were washed five times
with 0.8 ml of WBKT with a shaking period of 3 min between
the washing steps. Bound complexes were then eluted with 8 M
urea and quantified in a scintillation counter.
Gel electrophoresis of in vitro translations
For gel electrophoresis of translation products, in vitro trans-
lations were carried out for 25 min in the presence of
[35S]methionine. Release of protein from ternary complexes
was achieved by adding 10-fold concentrated EDTA in Tris–
HCl buffer (pH 7.5) to a final concentration of 20 mM or by
adding 10-fold concentrated puromycin in the same buffer to a
final concentration of 2 mM and an additional incubation for
5 min at 37C. Soluble and insoluble fractions of 30 ml in vitro
translation mix were separated by immediate centrifugation at
21 000 g for 5 min at 4C. Acetone (120 ml) was added to the
supernatant, incubated for 30 min on ice and centrifuged again.
The pellet was dried and all fractions were resuspended in 27 ml
of TBS. RNA was digested by adding 2 ml of 50 mM MgCl2
and 1 ml of 1 mg/ml RNaseA and incubation for 20 min at 37C.
SDS loading buffer (15 ml) was added and, after heating, sam-
ples were subjected to reducing SDS gel electrophoresis on
a 12% polyacrylamide gel.
Phage purification
Phagemids were transformed into E.coli XL1-Blue and grown
on LB plates containing 1% glucose, 34 mg/ml chlorampheni-
col and 15 mg/ml tetracycline. A 5 ml volume of the same
medium was inoculated with single colonies and grown at
37C overnight. A 20 ml volume of 2YT medium containing
1% glucose, 34 mg/ml chloramphenicol and 15 mg/ml tetracyc-
line was inoculated with the overnight culture and grown at
37C to an A600 of 0.8. Then 10
11 pfu VCS M13 helper phage
(Stratagene) were added and the culture was incubated in a
water-bath for 45 min at 37C. After shaking for an additional
30 min at 37C, the cells were centrifuged and the medium was
replaced with 60 ml of 2YT containing 0.1 mM IPTG, 34 mg/ml
chloramphenicol and 25 mg/ml kanamycin. The culture was
shaken overnight at 30C and phages were precipitated from
the culture supernatant by incubation for 30 min with
one-quarter volume of PEG–NaCl solution (20% PEG 6000,
2.5 M NaCl) on ice. The pellets were redissolved in PBS, pH
7.4, and precipitated once again with PEG–NaCl solution.
After dissolution in PBS, phages were further purified by ultra-
centrifugation in a CsCl gradient as described (Bothmann and
Plu¨ckthun, 1998).
Phage ELISA
Phage ELISAs to detect binding to Nogo-66 fusion protein
were carried out under conditions similar to the binding assays
with ribosomal complexes: 1012 phages in TBST (pH 7.5) were
preincubated with or without ligand in the same buffer for
20 min and, after preincubation, paramagnetic beads coated
with Nogo-66 fusion protein were added and incubated as
described above. After washing, bound phages were detected
with anti-M13-antibody conjugated with horseradish peroxi-
dase (Pharmacia). Development was carried out by addition of
1:1 diluted BM Blue POD substrate (Roche) in PBST and the
reaction was stopped by addition of 1 M H2SO4 after defined
time periods.
Phage blots
Phage concentrations were determined spectrophotometrically;
1.5 · 1012 phages were subjected to a reducing 12% SDS–
PAGE and blotted on a PVDF membrane (Immobilon-P,
Millipore). Detection of g3p fusion proteins was carried
out with primary antibodies mouse anti-FLAG M1 (Sigma),
mouse anti-myc 9B11 (NEB) and the monoclonal antibody
10C3 recognizing the C-terminal domain of g3p (Tesar
et al., 1995).
Results
Characterization of the Nogo-66 domain
The LRR portion of the Nogoreceptor has been shown to be
necessary and sufficient for binding to the small extracellular
domain of Nogo, termed Nogo-66 (Fournier et al., 2002). In
order to probe the specific interaction of this part of Nogo with
the Nogoreceptor expressed in a display system format, we first
produced and characterized the recombinant Nogo-66 domain.
We expressed Nogo-66 either alone with an N-terminal Avi-tag
and a C-terminal His-tag or as a fusion to the C-terminus of
various fusion partners. The proteins were all expressed as
inclusion bodies in E.coli and purified by Ni-NTA affinity
chromatography under denaturing conditions. Recently, Li
et al. (2004) reported Nogo-66 to be insoluble in aqueous
buffer. Even though we also found Nogo-66 to be highly
aggregation prone and completely insoluble at neutral pH,
the solubility of Nogo-66 increases markedly upon refolding
and storage at higher pH values. Nogo-66 obtained by fast
dilution refolding under conditions above pH 8.0 is soluble
up to a concentration of 25 mM, independent of the buffer
system employed. The presence of N-terminal fusion partners
further increases the solubility of Nogo-66 and its half-life in
solution. Figure 1 shows size-exclusion chromatographic pro-
files of (A) non-fused Nogo-66 and (C) Nogo-66 fused to
protein D. While a certain fraction of refolded protein remains
as soluble aggregates after refolding—eluting at the void vol-
ume of the column—75% of pD–Nogo-66 and 65% of non-
fused Nogo-66 elute as a single symmetric peak. The apparent
molecular masses calculated from the elution volumes are 34.7
and 19.8 kDa, compared with theoretical values of 23.6 and
11.0 kDa, respectively. Even though these apparent molecular
masses correspond to values only slightly below those of the
respective homodimers, molecular mass determinations by sta-
tic light scattering of the pD–Nogo-66 fusion result in a
molecular mass of 22.9 6 6.0 kDa (theoretical mass: 23.6
kDa), clearly indicating that the major fraction of refolded
material is indeed monomeric. We were not able to obtain
reliable light scattering data for non-fused Nogo-66, owing
to its small molecular mass and the interference of the strong
scattering signal of insoluble aggregates. However, the similar
elution patterns and the fact that Nogo-66 complexed with the
anti-Nogo-66 antibody alFv1 (see below) results only in com-
plexes of 1:1 stoichiometry (data not shown) indicate that non-
fused Nogo-66, like pD–Nogo-66, is monomeric. CD spectra of
Nogo-66 (Figure 1B) show a broad negative feature from 205
to 220 nm, indicative of a significant proportion of a-helical
secondary structure content in the protein. The measured spec-
tra are independent of the buffer system used (phosphate, Tris
or borate buffer). In agreement with the data of Li et al. (2004),
Nogo-40, which only comprises the 40 N-terminal amino acids
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of Nogo-66, was found to be unstructured under the same
conditions (data not shown). Together, these data suggest
that Nogo-66 may be the functional and structural unit neces-
sary for forming a compact domain.
Constructs of the Nogoreceptor ligand binding domain for
ribosome display and phage display
In order to examine whether the Nogoreceptor ligand binding
domain can be displayed in an active form in a ribosome
display or phage display format, the gene fragment encoding
residues 24–331 of the Nogoreceptor (NR) was inserted
into standard vectors for ribosome display and phage display
(Figure 2A). For ribosome display, we used a C-terminal spacer
sequence consisting of residues 20–109 of lambda phage
capsid protein D (Forrer and Jaussi, 1998; Matsuura and
Plu¨ckthun, 2003). For phage display, we used a phagemid
system in which NR was placed behind a phoA signal sequence
and fused to the C-terminal domain of the gene 3 protein of
phage M13 (g3p). In both cases tags allow to detect the display
of the respective fusion proteins.
The ligand binding domain of the Nogoreceptor contains two
free cysteine residues in the LRR core region, in addition to the
conserved disulfide bridges in the capping modules (Figure 2).
LRR modules are defined by a unique consensus sequence and
the consensus residues are responsible for the proper packing of
the hydrophobic core (Kobe and Deisenhofer, 1995). Both free
cysteine side chains in the LRR are buried and their positions
correspond to positions of the LRR consensus motif that are
otherwise almost exclusively occupied by leucine and aspar-
agine, respectively. We were concerned that, in phage display,
an illegitimate oxidation in the bacterial periplasm, en route to
the phage coat, might covalently trap a misfolded structure and
prevent its incorporation into the phage. In order to minimize
this problem, Cys80 and Cys140 were mutated to the consensus
residues Leu and Asn, respectively (Figure 2B). Because the
LRR consensus motif is restored by these mutations, no neg-
ative influence on hydrophobic core packing or folding effi-
ciency would be expected. Replacement of Cys140 by Asn is
even likely to introduce an additional H-bond by completing
the continuous arrangement of hydrogen bonds of the stacked
asparagine side chains, commonly referred to as ‘asparagine
ladder’ (Kobe and Deisenhofer, 1995), which connects the
turns of neighbouring repeats. These constructs were then
evaluated in ribosome display and phage display.
Ribosomal complexes of the Nogoreceptor are able to
bind to its cognate ligand Nogo-66
The basis of a phenotypic selection for ligand binding is that
the displayed protein can fold correctly into its native structure.
Although no functional or soluble Nogoreceptor could so far be
produced in the bacterial cytoplasm, periplasm or by refolding
from inclusion bodies (data not shown), we found, surprisingly,
Fig. 2. (A) Schematic representation of the fusion constructs used for phage display (upper graph) and ribosome display (lower graph). (B) Schematic representation of
variants of the Nogoreceptor ligand binding domain (residues 24–331) used in these studies. The conserved disulfide bridges in the N- and C-terminal ‘capping
modules’ (LRR-NT, LRR-CT) and the free cysteines in the LRR core region are indicated. Both free cysteines are mutated to the respective consensus residues in
variant NRC. The LRR core region is composed of 8.5 LRR modules. The mutations in the far C-terminal overhang of 22 amino acids represent the changes of the
macaque to the human receptor sequence.
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that in vitro expression in the ribosome display format, with
Nogoreceptor still bound to the ribosome, indeed yielded
soluble ribosomal complexes displaying full-length Nogore-
ceptor domain. In order to test whether the displayed proteins
are correctly folded and functional, we investigated the inter-
action of these ternary complexes with the cognate ligand
Nogo-66. We established an assay in which Nogo-66 fusion
proteins are immobilized on paramagnetic beads (M270-
Epoxy, Dynal) and binding of ternary complexes is measured
by radioimmunoassay (RIA) after in vitro translation of the
Nogoreceptor domain in the presence of [35S]methionine
(Figure 3). Binding signals that are higher than background
are only obtained on beads coated with Nogo-66 fusion pro-
teins. Signals are significantly lower on beads that are coated
with the same amount of fusion partner but missing the Nogo-
66 portion or on beads that are coated with protein G, used as a
control. In order to exclude that either ribosomes or RNA
interact non-specifically with Nogo-66, we also checked the
interaction of ribosomal complexes for which the Nogore-
ceptor domain is replaced with protein D or a soluble protein
derived from a random sequence library (Matsuura and
Plu¨ckthun, 2003). Indeed, no binding was observed for
ribosomes displaying these control proteins. Moreover, binding
signals can be inhibited by the addition of free Nogo-66 fusion
protein, clearly showing the ability of ternary complexes to
interact with Nogo-66 both on the surface and in solution.
The observed IC50 is 2 mM (see below). In order to deter-
mine quantitatively the affinity between Nogoreceptor and
Nogo-66 in this assay, the coating density of the ligand has
to be chosen low enough to prevent shifting of the equilibrium
in the liquid phase (Friguet et al., 1985; Hetherington, 1990).
Owing to the technical difficulties associated with the deter-
mination of the amount of immobilized ligand that is function-
ally active, and also the number of added ternary ribosomal
complexes, we are not able to determine an accurate dissoci-
ation constant. Therefore, the measured IC50 value measured in
this assay solely represents an upper limit for KD. Even so, the
affinity seems still to be lower than the apparent affinities
measured in cell-based assays, which were determined to be
in the nanomolar range (Fournier et al., 2001). Interestingly,
the binding affinity also has been reported to be weaker in
coimmunoprecipitation experiments with purified ligand
labelled)
Fig. 3. RIA of ribosomal complexes displaying [35S]methionine-labelled Nogoreceptor domains. (A) Schematic representation of the binding assay. (B) Binding of
ribosomal complexes displaying in vitro translated and 35S-labelled Nogoreceptor to Nogo-66 fusion proteins, immobilized on paramagnetic beads, was investigated.
Immobilized refers to the protein coated on the magnetic beads, displayed to the protein translated and connected to the ribosomes and competitor to protein present in
solution. As negative controls, the binding of Nogoreceptor-displaying ternary complexes to other proteins was investigated: binding to beads coated with protein G
(white bars) or to beads coated with lambda phage protein D missing the C-terminal Nogo-66 insertion (light grey column). As further negative controls the non-
specific binding of ribosomal complexes displaying unrelated proteins on immobilized pD–Nogo-66 was assessed: binding of ribosomal complexes only displaying
protein D (vertically striped bars) or a protein derived from a random sequence library (horizontally striped lines). Black bars represent specific binding to Nogo-66,
being immobilized either as a fusion to protein D or as a fusion to thioredoxin. Signals observed when the free ligand Nogo-66 is added as a competitor at a
concentration of 4 mM (grey bars). All reactions were performed in the presence of 5 mg/ml BSA and 250 mg/ml S.cerevisiae RNA. Signals are normalized to the
binding signal of the respective Nogo-66 fusion protein.
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binding domain used for crystallization (He et al., 2003). It
should be noted, however, that cell binding assays on
Nogoreceptor-displaying cells are crucially different from in
vitro binding assays on immobilized Nogo-66 ligand. Like the
purified ligand binding domain, Nogoreceptor displayed on
ribosomes is most likely monomeric, resulting in a binding
stoichiometry of 1:1. In contrast, multimerization has been
shown to occur for GPI-linked Nogoreceptor on the cell surface
(Fournier et al., 2002), which most likely leads to avidity
effects that will have a drastic influence on the apparent KD.
Importantly, our results also show that the non-glycosylated
LRR core protein of the Nogoreceptor is sufficient to mediate
binding to Nogo-66.
Nogoreceptor is not amenable to phage display
In contrast to the results obtained with ribosome display, M13
phages produced in cells harbouring phagemid vectors encod-
ing the Nogoreceptor domain which is fused to the C-terminal
part of g3p showed no specific binding to Nogo-66 immobil-
ized on paramagnetic beads, as determined by phage ELISA
(Figure 4A). As a positive control, the single-chain Fv (scFv)
fragment alFv1 was used, which we selected previously to bind
specifically to Nogo-66 (B.Schimmele, unpublished results)
obtained by phage panning with the fully synthetic Human
Combinatorial Antibody Library (HuCAL) (Knappik et al.,
2000). The high sensitivity of phage ELISA (because of the
signal amplification inherent in anti-p8 antibodies) allows even
the detection of low-affinity binding and a small number of
phages displaying functional protein, suggesting almost a com-
plete absence of functional Nogoreceptor. For the functional
display on phages, proteins have to be transported to the peri-
plasmic space, where protein folding of g3p fusions occurs in a
membrane-bound state prior to incorporation into the phage. In
the monovalent phage display system used, wild-type g3p from
the helper phage competes with the g3p fusion proteins for
incorporation into the phage particles, ensuring that phages are
properly assembled and infectivity is maintained. As a result,
phage titres are usually independent of the displayed protein.
The display level, i.e. the amount of fusion protein incorpor-
ated in the phage coat is dependent, at least partly, on the
amount of correctly folded protein in the periplasm (Bothmann
and Plu¨ckthun, 1998). We used tags, placed N- and C-
terminally of the NR domain, to check whether the LRR
protein is indeed displayed on the phage. Whereas the control
scFv is detected by antibodies directed against both tags,
neither variant of the Nogoreceptor domain can be detected
(Figure 4B). This lack of incorporation into the phage is most
likely caused by severe aggregation of the translated fusion
protein prior to phage assembly, either in the periplasm or
perhaps even before the transport through the inner membrane.
Hence phage display cannot be used for these receptor domains.
Ribosomal complexes provide a favourable environment
for the folding and functional display of Nogoreceptor
Different reasons could account for the soluble expression of
NR in active form in the ribosome display format. Even though
the presence of eukaryotic protein disulfide isomerase (PDI) in
the translation mix might be crucial for the formation of correct
disulfide bridges and prevent aggregation upon misfolding or
formation of intermolecular disulfides, translation in the
absence of PDI or under different redox conditions did not
result in either a significant decrease in soluble ternary com-
plexes or in a significant reduction of binding to pD–Nogo-66
(data not shown), indicating that the formation of disulfide
Fig. 4. (A) Phage ELISA on paramagnetic beads coated with pD–Nogo-66. Black bars represent binding of phage and grey columns binding of phages in the presence
of 4 mM pD–Nogo-66 as competitor. As a negative control, phages displaying an unrelated scFv antibody were used. (B) Phage blot. Detection of the indicated g3p
fusion proteins displayed on phages; 1.5 · 1011 phages were applied per lane and detected either with an antibody directed against the C-terminal domain of g3p (left
panel) or with antibodies detecting only the fusion proteins via the fused tags (middle and right panels).
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bridges in the capping modules is not crucial for attaining a
native-like conformation of the LRR portion of the domain.
Several observations indicate instead that in fact the tethering
of proteins to the ribosome and RNA is the major reason why
aggregation is prevented.
Previously, it had been observed that a protein derived from
a random sequence library with a strong tendency to form
amyloid-like fibrils still resulted in soluble ternary complexes,
suggesting that the ribosome and the connected RNA can act as
solubility-enhancing fusion partners and may sterically block
aggregation (Matsuura and Plu¨ckthun, 2003). We therefore
wanted to test whether the solubility of in vitro translated
receptor domains is directly linked to their presence in ternary
complexes. Disintegration of ternary complexes can be
achieved by adding either EDTA or puromycin, leading to a
release of translated protein from the ribosome. After defined
times of translation, EDTA-containing buffer of the same pH
was added to the translation mix, briefly incubated and aggreg-
ated protein was collected by centrifugation. Upon addition of
EDTA, a strong increase in the amount of aggregated receptor
and an equivalent decrease in the amount of soluble receptor
can be observed for in vitro translated Nogoreceptor and also
for in vitro translated biglycan, a domain of similar structure
(Figure 5). Upon addition of puromycin, a strong effect on the
solubility of in vitro translated biglycan is observed, but effects
on the solubility of displayed Nogoreceptor are small (data not
shown). In contrast, control proteins which are not aggregation
prone remain in solution upon addition of either reagent. These
data suggest that aggregation indeed occurs to a certain degree
post-translationally upon protein release from the ribosome.
In addition, expression in the context of ribosomal complexes
allowed the soluble display of other aggregation-prone
receptor domains, such as the extracellullar domain of the
luteinizing hormone receptor or decorin (data not shown),
suggesting that these observations represent a general feature
of ribosome display. The potential of the ribosome to act as a
solubility-enhancing fusion partner has also been used in cova-
lent coupling of inclusion body-forming proteins to the ribo-
some in order to make them soluble (Sorensen et al., 2004). It is
noteworthy that aggregation is not quantitative and a certain
fraction of protein remains in solution even after EDTA-
induced release from ribosomal complexes. Hence it is possible
that the aggregating portion simply represents the fraction
which has not attained the correct native fold, while the remain-
ing soluble fraction has folded into a native-like structure,
while being forced to stay out of contact with other receptor
molecules. As non-productive intermolecular interactions lead-
ing to aggregation and productive intramolecular interactions
responsible for attaining the native structure compete with each
other, the longer persistence of the protein in ternary
complexes—compared with the situation in vivo—could
enable the polypeptide chain to acquire a native-like
fold before intermolecular interactions and subsequent
aggregation occur.
Binding studies with the displayed Nogoreceptor domain
We first wanted to check whether the introduced consensus
mutations substituting the free cysteines in the LRR core region
would have any influence on the display rate or the affinity of
the displayed domain. By direct comparison with the wild-
type, we observed a slight increase in the display rate (1.5-
fold) of NRC as judged by the number of soluble complexes
captured by an anti-His-tag antibody with subsequent immuno-
precipitation on paramagnetic beads coated with protein G
(Figure 6A). The inhibition patterns of both variants do not
display significant differences (Figure 6B), showing that the
consensus mutations do not disturb the binding of ternary
complexes to Nogo-66.
The specific binding mode of Nogo-66 on the LRR domain
of the Nogoreceptor is still unclear and controversial. In cell-
based assays with deletion mutants of the Nogoreceptor, weak
binding activity of the LRR-CT region alone, but no binding
activity of a construct comprising only LRR-NT and the LRR
core, has been reported (Wang et al., 2002). A larger series of
deletion mutants has been investigated by Fournier et al.
(2002), in which capping modules and any two adjacent repeat
modules were deleted at a time. However, no binding was
detected for any of the deletion mutants and the authors con-
cluded that binding activity is dispersed over the LRR domain.
Nevertheless, as mentioned previously, effects of receptor
multimerization or interactions with coreceptor might have a
strong influence on the binding activity measured in cell-
based assays.
We therefore tested whether binding activity can be detected
for LRR-CT alone or, conversely, deletion of LRR-CT will
lead to a drastic reduction in binding activity towards Nogo-66
in our in vitro assay. In accordance with the results of Wang
et al. (2002), we are able to detect weak binding activity for the
C-terminal capping module alone. However, in contrast to the
results of Fournier et al. (2002), deletion of LRR-CT does not
lead to a severe decrease in the binding signal (Figure 7),
showing that indeed the LRR core region makes the major
contribution to the binding to Nogo-66.
Discussion
We have expanded the applicability of ribosome display to
mammalian receptor domains. Despite the high tendency of
Fig. 5. In vitro translation of ribosome display constructs encoding the
Nogoreceptor domain, biglycan core protein or protein D as a soluble
control protein. After 25 min of translation, EDTA was added to release
translated proteins from the ribosome and the sample was incubated for an
additional 5 min. Soluble and insoluble fractions were separated by
immediate centrifugation at 4C, treated as described in Materials and
methods and analysed by SDS gel electrophoresis and autoradiography.
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these protein domains to form insoluble aggregates upon
heterologous expression in E.coli, both in the cytoplasm and
the periplasm and upon refolding from inclusion bodies in
vitro, they can apparently fold while still held by the ribosome.
Many cell surface receptors, including the Nogoreceptor, are
glycosylated. Several observations indicate active roles of gly-
can side chains for protein folding, such as facilitating inter-
actions with certain folding modulators (Trombetta and
Helenius, 1998), increasing the solubility of native state pro-
teins and presumably folding intermediates or even increasing
the thermodynamic stability of the native state (Giraud et al.,
1992; van Zuylen et al., 1997). It is therefore an intriguing
hypothesis that the ribosome display format, with the RNA and
the ribosome still connected to the nascent polypeptide, might
provide a similar environment which enhances the solubility of
partially folded species or even sterically blocks the aggrega-
tion of displayed proteins. If folding needs to proceed over a
comparatively long time-scale, this environment might allow
the protein to acquire a native-like fold before intermolecular
interactions and subsequent aggregation occur. This special
environment in ternary complexes, being composed of the
receptor, the ribosome and RNA, allows the soluble and func-
tional expression in a conventional in vitro translation set-up,
provided that the mRNA has no stop codon, the solution is
cooled and the ribosome is stabilized by a suitable buffer. This
approach now allows us to test rapidly mutants in vitro when
the pure recombinant protein is otherwise inaccessible or can
only be obtained from mammalian production. Furthermore,
this should make it possible to evolve variants of the Nogore-
ceptor with higher affinity, stability or solubility (Jermutus
et al., 2001; Matsuura and Plu¨ckthun, 2003). Even though
phage display represents another versatile tool for evolving
proteins towards higher stability (Jung et al., 1999) or higher
resistance to aggregation (Jespers et al., 2004), this methodo-
logy is limited to proteins that can be functionally displayed on
filamentous phage. Other important applications include com-
binatorial approaches to identify and dissect residues important
for binding (Weiss et al., 2000). Therefore, the ternary com-
plexes in ribosome display allow the folding of aggregation-
prone proteins in vitro and to make such proteins accessible to
analytical dissection and an evolutionary improvement.
Besides the previously mentioned advantages of the ribo-
some display technology such as large library sizes and the
powerful built-in evolution process, our results suggest that
ribosome display can also be a versatile analytical tool for
aggregation-prone proteins and other mammalian receptor
molecules whose binding activity is not directly dependent
on post-translational modifications. This system does not
only allow the investigation of structure–function relationships
in a combinatorial way, but has the potential to evolve receptor
domains with properties more suitable for drug-related applica-
tions. Such engineered variants of the Nogoreceptor domain
may be useful as therapeutic agents for treating spinal chord
injuries, stroke or traumatic head injuries.
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